HALIFAX, Nov. 15 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF), a global market leader in premium rapid diagnostic solutions, announced today that its Reveal G3 Rapid HIV-1 Antibody Test ("Reveal G3") has been approved for purchase by the U.S. Agency for International Development ("USAID"), resulting in the placement of Reveal G3 on USAID's rapid HIV test procurement list. USAID's office of HIV/AIDS is responsible for leading the Agency's efforts within the President's Emergency Plan for AIDS Relief ("PEPFAR"); a $15 billion multifaceted approach to combating HIV and AIDS in over 100 countries, with particular emphasis on fifteen focus countries in Africa, Asia and Latin America. MedMira's inclusion on this procurement list enables Reveal G3 to be purchased for USAID-funded projects, and permits countries receiving USAID funding to purchase Reveal G3 under the PEPFAR program.
